Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

[1]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[2]  M. Domanski,et al.  Beta-blocker Evaluation of Survival Trial , 2000 .

[3]  N. Sharma,et al.  Racial differences in patients with heart failure , 1999, Clinical cardiology.

[4]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[5]  P. Whelton,et al.  Plasma insulin levels and incidence of hypertension in African Americans and whites. , 1999, Archives of internal medicine.

[6]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[7]  T. Yue,et al.  Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. , 1998, Progress in cardiovascular diseases.

[8]  E. Philbin,et al.  Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. , 1998, The American journal of cardiology.

[9]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[10]  C. Lang,et al.  Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. , 1997, Hypertension.

[11]  R. Marfella,et al.  Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension , 1997, Annals of Internal Medicine.

[12]  J. Sorof,et al.  Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. , 1997, Hypertension.

[13]  S. Coughlin,et al.  What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, Dilated Cardiomyopathy Study. , 1997, Journal of the National Medical Association.

[14]  A. J. Walker,et al.  Cardiovascular and plasma catecholamine response to static exercise in normotensive blacks and whites. , 1997, Ethnicity & health.

[15]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[16]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[17]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[18]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[19]  S. Jacob,et al.  Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study , 1996, Journal of hypertension.

[20]  E. Saunders,et al.  Hypertension in minorities: blacks. , 1995, American journal of hypertension.

[21]  Arleen F. Brown,et al.  Hospitalization for congestive heart failure. Explaining racial differences. , 1995, JAMA.

[22]  P. Sever,et al.  Racial differences in cardiac structure and function in essential hypertension , 1994, BMJ.

[23]  A. Sherwood,et al.  Responsiveness to α- and β-Adrenergic Receptor Agonists Effects of Race in Borderline Hypertensive Compared to Normotensive Men , 1993 .

[24]  D J Reda,et al.  Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo , 1993 .

[25]  R. Cooper,et al.  Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. , 1990, Archives of internal medicine.

[26]  L. Haywood.  Hypertension in minority populations. Access to care. , 1990, The American journal of medicine.

[27]  J. Dimsdale,et al.  Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. , 1987, Hypertension.

[28]  L. Cubeddu,et al.  A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. , 1986, JAMA.

[29]  B. Materson,et al.  Monotherapy with labetalol compared with propranolol. Differential effects by race. , 1985, Journal of clinical hypertension.

[30]  N. Fineberg,et al.  Sodium sensitivity in normotensive human subjects. , 1983, Annals of internal medicine.

[31]  G. Berenson,et al.  Racial differences in blood pressure control. , 1979, Science.

[32]  E. Braunwald,et al.  The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.

[33]  E. Braunwald,et al.  Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. , 1963, The American journal of medicine.

[34]  J. Wright,et al.  Essential hypertension: racial/ethnic differences in pathophysiology. , 1996, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[35]  J. Dimsdale,et al.  Racial Differences in Epinephrine and β2-Adrenergic Receptors , 1995 .

[36]  Pratt Jh,et al.  The interaction of norepinephrine excretion with blood pressure and race in children. , 1992 .

[37]  R. Holle,et al.  Renal vasculature in essential hypertension: racial differences. , 1978, Annals of internal medicine.